Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Sareum hails year of progress as it readies for another key period in its development

The AIM-listed group, whose focus is cancer and autoimmune diseases, licensed its SRA737 to US firm Sierra Oncology just over a year ago
cancer cells
Chk1 inhibitors use the body’s immune system to attack cancer cells. They have scored some success in treating metastatic melanoma and Hodgkin lymphoma

It has been a year of significant progress for Sareum Holdings PLC (LON:SAR) – one that’s seen headway with its lead drug candidate and success in securing its immediate funding needs.

The AIM-listed group, whose focus is cancer and autoimmune diseases, licensed its SRA737 to US firm Sierra Oncology just over a year ago.

READ: Sareum chairman hails “year of significant progress” and looks ahead to busy 2018

“Sierra is highly committed, well-funded and has proven experience in oncology drug development,” said chairman Stephen Parker at the company’s annual meeting.

An update on SRA737’s development programme is due late February, while data from studies will be presented in the second half of next year.

IN DETAIL: How Chk1 inhibitors work

The Sareum discovery is a new breed of targeted cancer drugs called checkpoint kinase 1, or Chk1 inhibitors.

In simple, layman’s terms, Chk1 inhibitors use the body’s immune system to attack cancer cells. They have scored some success in treating metastatic melanoma and Hodgkin lymphoma.

Funded and working on the drug pipeline

While SRA737’s progress will be closely monitored, the company does have a pipeline of other candidates with plenty of promise.  

And Sareum has been using the almost £2mln it has already received from partner Sierra, as well as a recent £700,000 fundraise to advance these programmes.

It has made encouraging progress with its TYK2 inhibitors and is on track to complete the preclinical development of its Aurora+FLT3 programme for acute leukaemias.

The firm is continuing to talk with potential partners with a view to securing licensing deals similar to the one it inked with Sierra.

On the lookout

It is also on the lookout for new research programmes – both from its own in-house discovery platform and from outside the business.

“The directors consider the year 2017 to have been transformational for Sareum, and I would like to thank our shareholders for their continued support and look forward to providing further updates on progress in 2018,” Parker told the annual meeting.

The Sareum share price, up around 9% in the year to date, values the business at around £22mln.

Is that reflective of progress made to date and the potential value of the deal with Sierra?

Probably not: the headline worth of this collaboration is £238mln (US$319mln) to be paid in instalments and is subject to the company hitting certain research and development milestones. Sareum is entitled to 27.5% of all payments.

Hidden value

One only has to look at the share price of Sierra Oncology, which is listed on NASDAQ, to realise there is a disconnect between how the US and UK values cutting-edge life science businesses.

Sierra’s shares have more than doubled in value in the last three months, buoyed by the excitement around SRA737.

It means Sierra now has a market capitalisation of £132mln, making it six times larger than Sareum.

You suspect at some point British investors will see the glaring anomaly and act.

View full SAR profile View Profile

Sareum Holdings Plc Timeline

Related Articles

scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
September 25 2018
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use